Asset Details
Do you wish to reserve the book?
68GaGa-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
68GaGa-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Do you wish to request the book?
68GaGa-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
68GaGa-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
2020
Overview
In the United States, [68Ga]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first 68Ga-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), [68Ga]Ga-DOTA-TOC was already approved back in 2016. This radiopharmaceutical combines the radionuclide 68Ga with the somatostatin analogue DOTA-TOC for specific imaging of tumor cells expressing SSTRs. Such a targeting approach can also be used for therapy planning in the case of both localized as well as disseminated disease and potentially for the evaluation of treatment response.
Publisher
MDPI,MDPI AG
